News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Opko Health, Inc. Announces Commencement of U.S. Clinical Trial for Point of Care Technologies, LLC Prostate Specific Antigen Test


12/21/2011 7:23:44 AM

MIAMI--(BUSINESS WIRE)--OPKO Health, Inc. (NYSE: OPK) today announced the commencement of a multi-center clinical study of OPKO’s point-of-care diagnostic test for prostate specific antigen (PSA) utilizing its proprietary diagnostic platform. OPKO intends to submit its application to the U.S. Food and Drug Administration for approval of the assay in 2012.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES